首页 蛋白库 基因库 产品 会员服务
位置：首页 > 产品库 > Netarsudil(AR-13324)
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Netarsudil(AR-13324)
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Netarsudil(AR-13324)图片
CAS NO:1253952-02-1
包装与价格：
包装价格(元)
2mg询价
5mg询价

Cas No.1253952-02-1
别名2,4-二甲基苯甲酸[4-[(1S)-1-(氨基甲基)-2-(6-异喹啉基氨基)-2-氧代乙基]苯基]甲基酯二盐酸盐
化学名(R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dihydrochloride
Canonical SMILES[H]Cl.[H]Cl.O=C(OCC1=CC=C([C@H](CN)C(NC2=CC3=C(C=NC=C3)C=C2)=O)C=C1)C4=CC=C(C)C=C4C
分子式C28H29Cl2N3O3
分子量526.45
溶解度≥ 26.3mg/mL in Water with ultrasonic and warming
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Ki: 0.2-10.3 nM

Netarsudil (AR-13324) is a ROCK inhibitor.

The Rho kinases are serine/threonine protein kinases existing as 2 isoforms, ROCK1 and ROCK2, which are widely expressed in various tissues, such as the trabecular meshwork. ROCK can promote the assembly of actin stress fibers and focal adhesions and can also regulate cell contraction and motility.

In vitro: Previous study showed that at the cellular level, netarsudil had been shown to be able to induce loss of actin stress fibers, cell shape changes, loss of focal adhesions, as well as changes in extracellular matrix composition of TM cells [1].

In vivo: Animal efficacy study found that the topical treatment of netarsudil was able to affect both proximal (trabecular meshwork and Schlemm's Canal) and distal portions (intrascleral vessels) of the mouse conventional outflow tract [2].

Clinical trial: Previous two phase II clinical trials showed that netarsudil 0.02% treatment was shown to produce significant DIOPs that ranged from 5.7 to 6.3 mmHg after four weeks of dosing in patients with glaucoma and ocular hypertension. In addition, it was found that netarsudil was well tolerated, with trace to mild hyperemia being the most frequently reported adverse event. Currently, netarsudil is in phase III clinical trials for the treatment of ocular hypertension and open-angle glaucoma [1].

References:
[1] Sturdivant JM et al.  Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. Bioorg Med Chem Lett. 2016 May 15;26(10):2475-80.
[2] Li G et al.  Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes. Eur J Pharmacol. 2016 Sep 15;787:20-31.

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024